Neuralgia News and Research

RSS
Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.
Teh Seng’s generic Lidoderm manufacturing facility in Taiwan successfully completes FDA cGMP audit

Teh Seng’s generic Lidoderm manufacturing facility in Taiwan successfully completes FDA cGMP audit

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

AANS, CNS urge Congress to restore Medicare payments for stereotactic radiosurgery

AANS, CNS urge Congress to restore Medicare payments for stereotactic radiosurgery

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept fourth quarter revenue decreases to $0.1 million

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

EpiCept third quarter revenue increases to $0.9 million

EpiCept third quarter revenue increases to $0.9 million

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Depomed third quarter 2012 revenue increases to $33.3 million

Depomed third quarter 2012 revenue increases to $33.3 million

Neuros Medical honored as most promising startup

Neuros Medical honored as most promising startup

Population Health Management discusses latest information on shingles and PHN

Population Health Management discusses latest information on shingles and PHN

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Treatments for peripheral neuropathic pain compared

Treatments for peripheral neuropathic pain compared

Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer’s Lyrica does not affect reproductive function in healthy males

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.